Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early adjunctive vasopressin for septic or vasodilatory shock in ICU feasibility trial
ACTRN12626000338369Phase 3Not yet recruiting
- Sponsor
- Austin Health
- Start
- Jun 2026
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of vasopressin in septic shock, Vasoplegia and hypotension (2 arms), sponsored by Austin Health. Primary endpoint: Feasibility of early adjunctive vasopressin administration. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
vasopressin
03
Conditions
septic shockVasoplegiahypotension
Beyond the preview
Go deeper on ACTRN12626000338369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000338369.